Stockwatch: Intercepting The Falling Knives Of NASH
Misperceptions Of Safety And Efficacy Plus The Invalidation Of A Surrogate Marker Hit Intercept
A complete response letter from the FDA knocked Intercept’s stock price for six, but perhaps the FDA is sending wider messages about NASH.
